Cristina M Arce1, Jinnie J Rhee2, Katharine L Cheung3, Haley Hedlin2, Kristopher Kapphahn2, Nora Franceschini4, Roberto S Kalil5, Lisa W Martin6, Lihong Qi7, Nawar M Shara8, Manisha Desai2, Marcia L Stefanick2, Wolfgang C Winkelmayer9. 1. Stanford University School of Medicine, Palo Alto, CA; Ohio State University, Columbus, OH. 2. Stanford University School of Medicine, Palo Alto, CA. 3. Stanford University School of Medicine, Palo Alto, CA; University of Vermont, Burlington, VT. 4. University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC. 5. University of Iowa Carver College of Medicine, Iowa City, IA. 6. George Washington University, Washington, DC. 7. University of California, Davis, Davis, CA. 8. MedStar Health Research Institute, Hyattsville, MD. 9. Stanford University School of Medicine, Palo Alto, CA; Baylor College of Medicine, Houston, TX. Electronic address: winkelma@bcm.edu.
Abstract
BACKGROUND: Kidney disease disproportionately affects minority populations, including African Americans and Hispanics; therefore, understanding the relationship of kidney function to cardiovascular (CV) outcomes within different racial/ethnic groups is of considerable interest. We investigated the relationship between kidney function and CV events and assessed effect modification by race/ethnicity in the Women's Health Initiative. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: Baseline serum creatinine concentrations (assay traceable to isotope-dilution mass spectrometry standard) of 19,411 postmenopausal women aged 50 to 79 years who self-identified as either non-Hispanic white (n=8,921), African American (n=7,436), or Hispanic (n=3,054) were used to calculate estimated glomerular filtration rates (eGFRs). PREDICTORS: Categories of eGFR (exposure); race/ethnicity (effect modifier). OUTCOMES: The primary outcome was the composite of 3 physician-adjudicated CV events: myocardial infarction, stroke, or CV-related death. MEASUREMENTS: We evaluated the multivariable-adjusted associations between categories of eGFR and CV events using proportional hazards regression and formally tested for effect modification by race/ethnicity. RESULTS: During a mean follow-up of 7.6 years, 1,424 CV events (653 myocardial infarctions, 627 strokes, and 297 CV-related deaths) were observed. The association between eGFR and CV events was curvilinear; however, the association of eGFR with CV outcomes differed by race (P=0.006). In stratified analyses, we observed that the U-shaped association was present in non-Hispanic whites, whereas African American participants had a rather curvilinear relationship, with lower eGFR being associated with higher CV risk, and higher eGFR, with reduced CV risk. Analyses among Hispanic women were inconclusive owing to few Hispanic women having very low or high eGFRs and very few events occurring in these categories. LIMITATIONS: Lack of urinary albumin measurements; residual confounding by unmeasured or imprecisely measured characteristics. CONCLUSIONS: In postmenopausal women, the patterns of association between eGFR and CV risk differed between non-Hispanic whites and African American women.
RCT Entities:
BACKGROUND:Kidney disease disproportionately affects minority populations, including African Americans and Hispanics; therefore, understanding the relationship of kidney function to cardiovascular (CV) outcomes within different racial/ethnic groups is of considerable interest. We investigated the relationship between kidney function and CV events and assessed effect modification by race/ethnicity in the Women's Health Initiative. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: Baseline serum creatinine concentrations (assay traceable to isotope-dilution mass spectrometry standard) of 19,411 postmenopausal women aged 50 to 79 years who self-identified as either non-Hispanic white (n=8,921), African American (n=7,436), or Hispanic (n=3,054) were used to calculate estimated glomerular filtration rates (eGFRs). PREDICTORS: Categories of eGFR (exposure); race/ethnicity (effect modifier). OUTCOMES: The primary outcome was the composite of 3 physician-adjudicated CV events: myocardial infarction, stroke, or CV-related death. MEASUREMENTS: We evaluated the multivariable-adjusted associations between categories of eGFR and CV events using proportional hazards regression and formally tested for effect modification by race/ethnicity. RESULTS: During a mean follow-up of 7.6 years, 1,424 CV events (653 myocardial infarctions, 627 strokes, and 297 CV-related deaths) were observed. The association between eGFR and CV events was curvilinear; however, the association of eGFR with CV outcomes differed by race (P=0.006). In stratified analyses, we observed that the U-shaped association was present in non-Hispanic whites, whereas African American participants had a rather curvilinear relationship, with lower eGFR being associated with higher CV risk, and higher eGFR, with reduced CV risk. Analyses among Hispanic women were inconclusive owing to few Hispanic women having very low or high eGFRs and very few events occurring in these categories. LIMITATIONS: Lack of urinary albumin measurements; residual confounding by unmeasured or imprecisely measured characteristics. CONCLUSIONS: In postmenopausal women, the patterns of association between eGFR and CV risk differed between non-Hispanic whites and African American women.
Authors: Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort Journal: Lancet Date: 2010-05-17 Impact factor: 79.321
Authors: Lesley A Stevens; Christopher H Schmid; Tom Greene; Yaping Lucy Zhang; Gerald J Beck; Marc Froissart; Lee L Hamm; Julia B Lewis; Michael Mauer; Gerjan J Navis; Michael W Steffes; Paul W Eggers; Josef Coresh; Andrew S Levey Journal: Am J Kidney Dis Date: 2010-06-16 Impact factor: 8.860
Authors: Stacey E Jolly; Nilka Ríos Burrows; Shu-Cheng Chen; Suying Li; Claudine T Jurkovitz; Keith C Norris; Michael G Shlipak Journal: Clin J Am Soc Nephrol Date: 2011-07-22 Impact factor: 8.237
Authors: Morgan E Grams; Stephen P Juraschek; Elizabeth Selvin; Meredith C Foster; Lesley A Inker; John H Eckfeldt; Andrew S Levey; Josef Coresh Journal: Am J Kidney Dis Date: 2013-04-22 Impact factor: 8.860
Authors: Carmen A Peralta; Eric Vittinghoff; Nisha Bansal; David Jacobs; Paul Muntner; Bryan Kestenbaum; Cora Lewis; David Siscovick; Holly Kramer; Michael Shlipak; Kirsten Bibbins-Domingo Journal: Am J Kidney Dis Date: 2013-03-07 Impact factor: 8.860
Authors: Paul J Roderick; Richard J Atkins; Liam Smeeth; Adrian Mylne; Dorothea D M Nitsch; Richard B Hubbard; Christopher J Bulpitt; Astrid E Fletcher Journal: Am J Kidney Dis Date: 2009-04-25 Impact factor: 8.860
Authors: Dorothea Nitsch; Morgan Grams; Yingying Sang; Corri Black; Massimo Cirillo; Ognjenka Djurdjev; Kunitoshi Iseki; Simerjot K Jassal; Heejin Kimm; Florian Kronenberg; Cecilia M Oien; Andrew S Levey; Adeera Levin; Mark Woodward; Brenda R Hemmelgarn Journal: BMJ Date: 2013-01-29
Authors: Kunihiro Matsushita; Bakhtawar K Mahmoodi; Mark Woodward; Jonathan R Emberson; Tazeen H Jafar; Sun Ha Jee; Kevan R Polkinghorne; Anoop Shankar; David H Smith; Marcello Tonelli; David G Warnock; Chi-Pang Wen; Josef Coresh; Ron T Gansevoort; Brenda R Hemmelgarn; Andrew S Levey Journal: JAMA Date: 2012-05-09 Impact factor: 56.272
Authors: James P Lash; Ana C Ricardo; Jason Roy; Rajat Deo; Michael Fischer; John Flack; Jiang He; Martin Keane; Claudia Lora; Akinlolu Ojo; Mahboob Rahman; Susan Steigerwalt; Kaixiang Tao; Myles Wolf; Jackson T Wright; Alan S Go Journal: Am J Kidney Dis Date: 2016-05-19 Impact factor: 8.860
Authors: John Bellettiere; Steve Nguyen; Charles B Eaton; Sandy Liles; Deepika Laddu-Patel; Chongzhi Di; Marcia L Stefanick; Andrea Z LaCroix; Michael J LaMonte Journal: Am J Prev Cardiol Date: 2021-08-20